<status value="active"/><experimental value="true"/><date value="2026-06-30"/><publisher value="HL7 (FHIR Project)"/><contact><telecom><system value="url"/><value value="http://hl7.org/fhir"/></telecom><telecom><system value="email"/><value value="fhir@lists.hl7.org"/></telecom></contact><description value="A categorical pattern of glycosylation for a substance, typically derived from the production cell line or source organism. Applicable to proteins and structurally diverse substances (notably vaccines) per ISO 11238."/><jurisdiction><coding><system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/><code value="001"/><display value="World"/></coding></jurisdiction><caseSensitive value="true"/><valueSet value="http://hl7.org/fhir/ValueSet/substance-glycosylation-type"/><content value="complete"/><concept><code value="human"/><display value="Human"/><definition value="Glycosylation pattern from human cell lines (e.g. HEK293, PER.C6). No non-human glycan epitopes."/></concept><concept><code value="mammalian"/><display value="Mammalian (non-human)"/><definition value="Glycosylation pattern from non-human mammalian cell lines such as CHO, BHK or NS0. The most common pattern for therapeutic monoclonal antibodies."/></concept><concept><code value="old-world-monkey"/><display value="Old World Monkey"/><definition value="Glycosylation pattern from old world monkey cell lines such as Vero or COS. Often used for vaccine production."/></concept><concept><code value="mouse"/><display value="Murine"/><definition value="Glycosylation pattern from murine cell lines such as NS0 or SP2/0 hybridoma. Carries the alpha-1,3-galactose epitope which can be immunogenic in humans."/></concept><concept><code value="mammalian-afucosylated"/><display value="Mammalian, afucosylated"/><definition value="Glycosylation pattern from engineered mammalian cell lines lacking fucosyltransferase (e.g. Potelligent), producing antibodies with enhanced ADCC activity."/></concept><concept><code value="avian"/><display value="Avian"/><definition value="Glycosylation pattern from egg-derived or avian cell line production. Common for influenza vaccines."/></concept><concept><code value="insect"/><display value="Insect cell"/><definition value="Glycosylation pattern from insect cell expression systems such as baculovirus/Sf9. Used for some recombinant proteins and vaccines."/></concept><concept><code value="yeast"/><display value="Yeast"/><definition value="Native yeast glycosylation pattern (e.g. Saccharomyces cerevisiae). Examples include insulin and hepatitis B surface antigen."/></concept><concept><code value="yeast-humanised"/><display value="Yeast, humanised"/><definition value="Glycosylation pattern from glyco-engineered yeast (e.g. Pichia pastoris GlycoFi systems) that produces human-like glycan structures."/></concept><concept><code value="plant"/><display value="Plant"/><definition value="Glycosylation pattern from plant or plant cell culture production (e.g. taliglucerase alfa from carrot cells)."/></concept><concept><code value="bacterial"/><display value="Bacterial"/><definition value="Bacterial expression (typically E. coli). Generally unglycosylated; included for completeness when the substance has been characterised as such."/></concept></CodeSystem>

Generated Narrative: CodeSystem substance-glycosylation-type

This case-sensitive code system http://hl7.org/fhir/substance-glycosylation-type defines the following codes:

Code	Display	Definition
human	Human	Glycosylation pattern from human cell lines (e.g. HEK293, PER.C6). No non-human glycan epitopes.
mammalian	Mammalian (non-human)	Glycosylation pattern from non-human mammalian cell lines such as CHO, BHK or NS0. The most common pattern for therapeutic monoclonal antibodies.
old-world-monkey	Old World Monkey	Glycosylation pattern from old world monkey cell lines such as Vero or COS. Often used for vaccine production.
mouse	Murine	Glycosylation pattern from murine cell lines such as NS0 or SP2/0 hybridoma. Carries the alpha-1,3-galactose epitope which can be immunogenic in humans.
mammalian-afucosylated	Mammalian, afucosylated	Glycosylation pattern from engineered mammalian cell lines lacking fucosyltransferase (e.g. Potelligent), producing antibodies with enhanced ADCC activity.
avian	Avian	Glycosylation pattern from egg-derived or avian cell line production. Common for influenza vaccines.
insect	Insect cell	Glycosylation pattern from insect cell expression systems such as baculovirus/Sf9. Used for some recombinant proteins and vaccines.
yeast	Yeast	Native yeast glycosylation pattern (e.g. Saccharomyces cerevisiae). Examples include insulin and hepatitis B surface antigen.
yeast-humanised	Yeast, humanised	Glycosylation pattern from glyco-engineered yeast (e.g. Pichia pastoris GlycoFi systems) that produces human-like glycan structures.
plant	Plant	Glycosylation pattern from plant or plant cell culture production (e.g. taliglucerase alfa from carrot cells).
bacterial	Bacterial	Bacterial expression (typically E. coli). Generally unglycosylated; included for completeness when the substance has been characterised as such.